6:14 PM
 | 
Dec 05, 2012
 |  BC Extra  |  Company News

Genmab, Kyowa in bispecific antibody deal

Genmab A/S (CSE:GEN) will use its DuoBody technology to create bispecific antibodies against an undisclosed target from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151). Genmab said...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >